Please assess the completion status of the following clinical trial:

Trial Title: Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of A-T~* significant functional disability~* age over 4 years~Exclusion Criteria:~* major comorbidity: active malignancy requiring chemotherapy, kidney or liver failure~* sexually active~* known hypersensitivity to amantadine~* previous treatment with amantadine in the 2 months preceding the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 50 Months
- Healthy Volunteers: f

Study Arms:
- amantadine (PKMERZ) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).